JPS5916823A - トリプトファン・ピロラーゼ阻害用治療薬 - Google Patents
トリプトファン・ピロラーゼ阻害用治療薬Info
- Publication number
- JPS5916823A JPS5916823A JP58110026A JP11002683A JPS5916823A JP S5916823 A JPS5916823 A JP S5916823A JP 58110026 A JP58110026 A JP 58110026A JP 11002683 A JP11002683 A JP 11002683A JP S5916823 A JPS5916823 A JP S5916823A
- Authority
- JP
- Japan
- Prior art keywords
- methoxy
- methylsulfonylbenzamide
- diethylaminoethyl
- tryptophan pyrrolase
- inhibiting tryptophan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title description 4
- 102000057288 Tryptophan 2,3-dioxygenases Human genes 0.000 title description 3
- 108700016257 Tryptophan 2,3-dioxygenases Proteins 0.000 title description 3
- 230000001225 therapeutic effect Effects 0.000 title description 3
- 229940079593 drug Drugs 0.000 title description 2
- 230000002401 inhibitory effect Effects 0.000 title description 2
- JTVPZMFULRWINT-UHFFFAOYSA-N N-[2-(diethylamino)ethyl]-2-methoxy-5-methylsulfonylbenzamide Chemical compound CCN(CC)CCNC(=O)C1=CC(S(C)(=O)=O)=CC=C1OC JTVPZMFULRWINT-UHFFFAOYSA-N 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 229940126585 therapeutic drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 description 15
- 208000029650 alcohol withdrawal Diseases 0.000 description 5
- 208000020401 Depressive disease Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- SXJIZQPZESTWLD-UHFFFAOYSA-N N-[6-(propan-2-ylthio)-1H-benzimidazol-2-yl]carbamic acid methyl ester Chemical compound C1=C(SC(C)C)C=C2NC(NC(=O)OC)=NC2=C1 SXJIZQPZESTWLD-UHFFFAOYSA-N 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 208000003130 Alcoholic Neuropathy Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241001330002 Bambuseae Species 0.000 description 1
- 101100264195 Caenorhabditis elegans app-1 gene Proteins 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 108091006503 SLC26A1 Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- YAFQFNOUYXZVPZ-UHFFFAOYSA-N liproxstatin-1 Chemical compound ClC1=CC=CC(CNC=2C3(CCNCC3)NC3=CC=CC=C3N=2)=C1 YAFQFNOUYXZVPZ-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000001009 nucleus accumben Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8210565A FR2528702A1 (fr) | 1982-06-17 | 1982-06-17 | Application du n-(diethylaminoethyl) 2-methoxy-5-methylsulfonyl benzamide dans l'inhibition de la tryptophane pyrrolase |
| FR8210565 | 1982-06-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5916823A true JPS5916823A (ja) | 1984-01-28 |
| JPH0344050B2 JPH0344050B2 (enExample) | 1991-07-04 |
Family
ID=9275096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58110026A Granted JPS5916823A (ja) | 1982-06-17 | 1983-06-17 | トリプトファン・ピロラーゼ阻害用治療薬 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4485115A (enExample) |
| EP (1) | EP0099775B1 (enExample) |
| JP (1) | JPS5916823A (enExample) |
| AT (1) | ATE22800T1 (enExample) |
| DE (2) | DE3320187A1 (enExample) |
| FR (1) | FR2528702A1 (enExample) |
| HK (1) | HK56189A (enExample) |
| IT (1) | IT1203657B (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4909180A (en) * | 1986-12-27 | 1990-03-20 | Toyota Jidosha Kabushiki Kaisha | Assembly of electrostatic rotary sprayers |
| US4985283A (en) * | 1985-08-24 | 1991-01-15 | Toyota Jidosha Kabushiki Kaisha | Method and device for painting side outer panels of an automobile body |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0520325A1 (de) * | 1991-06-28 | 1992-12-30 | F.Hoffmann-La Roche & Co. Aktiengesellschaft | Verwendung von Monoaminoxidase-B-Hemmern zur Verhütung und Behandlung von Entzugserscheinungen nach Alkohol- und Drogenmissbrauch |
| EP1380292A1 (de) * | 2002-07-03 | 2004-01-14 | Mewicon med. wiss. Beratung GmbH | Tiaprid zur Behandlung von Depressionen |
| US20040224031A1 (en) * | 2003-05-06 | 2004-11-11 | Antonio Zorzano Olarte | Combination of amines and vanadium (IV)/(V) compounds for the treatment and/or prevention of diabetes mellitus |
| CN119384278A (zh) * | 2022-06-10 | 2025-01-28 | 上海日馨医药科技股份有限公司 | 治疗精神类疾病的方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5283621A (en) * | 1976-01-01 | 1977-07-12 | Yamanouchi Pharmaceut Co Ltd | N-benzyl-n, -benzylethyldiamine derivative |
| JPS5589220A (en) * | 1975-03-28 | 1980-07-05 | Ile De France | Remedy for controlling behavior abnormality |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE791677A (fr) * | 1972-07-19 | 1973-03-16 | Renfag Sa | Procede de preparation de n-(diethylaminoethyl)-2- methoxy-5-methylsulfonyl-benzamide |
| FR2243187B1 (enExample) * | 1973-09-10 | 1978-12-29 | Ile De France |
-
1982
- 1982-06-17 FR FR8210565A patent/FR2528702A1/fr active Granted
-
1983
- 1983-06-03 DE DE19833320187 patent/DE3320187A1/de not_active Withdrawn
- 1983-06-15 US US06/504,419 patent/US4485115A/en not_active Expired - Lifetime
- 1983-06-15 IT IT48506/83A patent/IT1203657B/it active
- 1983-06-16 EP EP83401236A patent/EP0099775B1/fr not_active Expired
- 1983-06-16 AT AT83401236T patent/ATE22800T1/de not_active IP Right Cessation
- 1983-06-16 DE DE8383401236T patent/DE3366834D1/de not_active Expired
- 1983-06-17 JP JP58110026A patent/JPS5916823A/ja active Granted
-
1989
- 1989-07-13 HK HK561/89A patent/HK56189A/xx not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5589220A (en) * | 1975-03-28 | 1980-07-05 | Ile De France | Remedy for controlling behavior abnormality |
| JPS5283621A (en) * | 1976-01-01 | 1977-07-12 | Yamanouchi Pharmaceut Co Ltd | N-benzyl-n, -benzylethyldiamine derivative |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4985283A (en) * | 1985-08-24 | 1991-01-15 | Toyota Jidosha Kabushiki Kaisha | Method and device for painting side outer panels of an automobile body |
| US4909180A (en) * | 1986-12-27 | 1990-03-20 | Toyota Jidosha Kabushiki Kaisha | Assembly of electrostatic rotary sprayers |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0099775A1 (fr) | 1984-02-01 |
| DE3320187A1 (de) | 1983-12-22 |
| ATE22800T1 (de) | 1986-11-15 |
| HK56189A (en) | 1989-07-21 |
| IT1203657B (it) | 1989-02-15 |
| IT8348506A0 (it) | 1983-06-15 |
| DE3366834D1 (en) | 1986-11-20 |
| FR2528702A1 (fr) | 1983-12-23 |
| US4485115A (en) | 1984-11-27 |
| FR2528702B3 (enExample) | 1985-04-19 |
| JPH0344050B2 (enExample) | 1991-07-04 |
| EP0099775B1 (fr) | 1986-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Haddad et al. | Aducanumab, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s disease: a comprehensive review | |
| Baeza-Flores et al. | Metformin: a prospective alternative for the treatment of chronic pain | |
| Moore et al. | Regulation of pain and itch by TRP channels | |
| Kaneko et al. | Transient receptor potential (TRP) channels: a clinical perspective | |
| Dicpinigaitis et al. | P2X3-receptor antagonists as potential antitussives: summary of current clinical trials in chronic cough | |
| Ma et al. | Protective effect of carnosine on subcortical ischemic vascular dementia in mice | |
| Singh et al. | Targeting the A3 adenosine receptor to prevent and reverse chemotherapy-induced neurotoxicities in mice | |
| Haddad et al. | Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s Disease: A comprehensive review | |
| Duan et al. | ACE2 activator diminazene aceturate ameliorates Alzheimer's disease-like neuropathology and rescues cognitive impairment in SAMP8 mice | |
| Singh et al. | Role of alpha-7-nicotinic acetylcholine receptor in Alzheimer's disease | |
| Ding et al. | Indirubin-3'-monoxime rescues spatial memory deficits and attenuates β-amyloid-associated neuropathology in a mouse model of Alzheimer's disease | |
| Barnes | Bronchodilators: basic pharmacology | |
| Merlo et al. | The ambiguous role of microglia in Aβ toxicity: Chances for therapeutic intervention | |
| Yan et al. | 7, 8-Dihydroxycoumarin alleviates synaptic loss by activated PI3K-Akt-CREB-BDNF signaling in Alzheimer’s disease model mice | |
| Ettcheto et al. | Peripheral and central effects of memantine in a mixed preclinical mice model of obesity and familial Alzheimer’s disease | |
| Cai et al. | Role of sigma-1 receptor in cocaine abuse and neurodegenerative disease | |
| Wang et al. | Protective effects of ACY-1215 against chemotherapy-related cognitive impairment and brain damage in mice | |
| van den Berg et al. | The novel TRPA1 antagonist BI01305834 inhibits ovalbumin-induced bronchoconstriction in guinea pigs | |
| Chen et al. | Tacrine (10)-hupyridone prevents post-operative cognitive dysfunction via the activation of BDNF pathway and the inhibition of AChE in aged mice | |
| JPS5916823A (ja) | トリプトファン・ピロラーゼ阻害用治療薬 | |
| Abe et al. | Targeting of lysosomal pathway genes for Parkinson's disease modification: insights from cellular and animal models | |
| Wild et al. | Safety and efficacy of naldemedine for the treatment of opioid-induced constipation in patients with chronic non-cancer pain receiving opioid therapy: a subgroup analysis of patients≥ 65 years of age | |
| Parekh et al. | AMPK-dependent autophagy activation and alpha-Synuclein clearance: a putative mechanism behind alpha-mangostin’s neuroprotection in a rotenone-induced mouse model of Parkinson’s disease | |
| Chen et al. | Structure–activity relationship study of psychostimulant synthetic cathinones reveals nanomolar antagonist potency of α-pyrrolidinohexiophenone at human muscarinic M2 receptors | |
| Liraz-Zaltsman et al. | Enhancement of brain d-serine mediates recovery of cognitive function after traumatic brain injury |